The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with ...

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older ...

The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly Provided by GlobeNewswire Jul 11, 2025, 8:35:00 AM ...

The CDC warns about the mosquito-borne chikungunya virus, which is gaining prevalence in South Asia and Europe, and affecting U.S. travelers.

Valneva plans to apply for EU regulatory approval in the second half of 2023. While Valneva's progress in developing a chikungunya vaccine is promising, experts suggest that more research is needed.

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...